Cargando…
Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19
Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals. In this report, we describe two cases of SARS-CoV-2–associated HUS...
Autores principales: | Leone, Valentina Fanny, Imeraj, Amantia, Gastoldi, Sara, Mele, Caterina, Liguori, Lucia, Condemi, Carmelita, Ruggenenti, Piero, Remuzzi, Giuseppe, Carrara, Camillo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920243/ https://www.ncbi.nlm.nih.gov/pubmed/35295324 http://dx.doi.org/10.3389/fphar.2022.842473 |
Ejemplares similares
-
Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome
por: Busutti, Marco, et al.
Publicado: (2020) -
Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab
por: Ellithi, Moataz, et al.
Publicado: (2021) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018) -
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)